Olaratumab, sold under the brand name Lartruvo, is a monoclonal antibody medication developed by Eli Lilly and Company for the treatment of solid tumors...
11 KB (951 words) - 07:29, 1 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
121 KB (13,799 words) - 17:37, 8 October 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
68 KB (5,999 words) - 20:41, 31 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
31 KB (3,430 words) - 05:24, 28 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
149 KB (15,702 words) - 00:28, 14 October 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
92 KB (8,729 words) - 10:30, 16 October 2024
to be a human polyclonal antibody (-pab) acting on the immune system. Olaratumab is an antineoplastic. Its name is composed of the components olara-t-u-mab...
38 KB (3,088 words) - 05:02, 8 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
13 KB (1,177 words) - 02:19, 4 September 2024
soravtansine Mogamulizumab Moxetumomab pasudotox Naxitamab Necitumumab Nivolumab Olaratumab Oportuzumab monatox Pembrolizumab Polatuzumab vedotin Prolgolimab Ramucirumab...
12 KB (821 words) - 02:57, 12 October 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
18 KB (1,573 words) - 05:19, 15 October 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
20 KB (1,566 words) - 08:58, 12 August 2024
Kesimpta mab human CD20 Y chronic lymphocytic leukemia, multiple sclerosis Olaratumab Lartruvo mab human PDGFRA Y cancer Oleclumab mab human 5'-nucleotidase...
136 KB (4,079 words) - 00:12, 12 October 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
14 KB (1,671 words) - 23:17, 4 September 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
42 KB (3,935 words) - 04:01, 30 April 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
24 KB (1,710 words) - 19:18, 30 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
34 KB (3,021 words) - 12:39, 5 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
26 KB (2,420 words) - 02:40, 26 September 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
5 KB (412 words) - 23:17, 19 June 2023
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
35 KB (4,573 words) - 09:59, 28 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
25 KB (2,086 words) - 02:24, 16 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
17 KB (1,708 words) - 22:30, 15 October 2024
members of the platelet-derived growth factor family. Lilly has developed Olaratumab, (LY3012207) a human IgG1 monoclonal antibody designed to bind to human...
96 KB (467 words) - 19:33, 6 August 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
19 KB (1,499 words) - 06:03, 16 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
43 KB (4,651 words) - 13:41, 27 July 2024
cystic fibrosis with CFTR F508del Atezolizumab Genentech metastatic NSCLC Olaratumab Eli Lilly soft-tissue sarcoma Nivolumab Bristol-Myers Squibb head and...
34 KB (180 words) - 17:05, 14 October 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
22 KB (1,787 words) - 05:10, 1 July 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
110 KB (10,692 words) - 03:53, 30 September 2024
patients with GIST tumors bearing the D842V mutation is under recruitment. Olaratumab (LY3012207) is a human IgG1 monoclonal antibody designed to bind to human...
29 KB (3,354 words) - 17:01, 9 December 2023
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
73 KB (6,455 words) - 18:49, 12 September 2024
Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL) SCF (c-Kit) Agonists: Ancestim Stem cell...
10 KB (1,179 words) - 18:31, 8 August 2024